Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the future of CAR-T and cellular therapy for multiple myeloma patients. With no currently approved CAR-T therapy for myeloma, he hopes a major advancement will be FDA approval of a BCMA-targeted CAR-T therapy in the near future. With regards to upcoming trials and research, there will be a focus on next-generation BCMA CAR T-cells, as well as newer targets such as GPRC5D and CD38. Trials of CAR-T-based combination therapies are being to be designed, as well as off the shelf CAR-T and CAR-NK treatments that may overcome the limitations of current therapies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.